ALLMedicine™ Candidiasis Center

Jan 19th, 2022 - Anticytokine autoantibodies are an important and emerging cause of disease. Anticytokine autoantibody-associated diseases include disseminated nontuberculous mycobacterial infection caused by anti-interferon- >= autoantibodies, severe mucocutaneou...

Jan 18th, 2022 - To estimate the association between potential risk factors and common vaginal infections, using nationwide primary healthcare and other national register. An open cohort study consisting of 2 357 711 women aged 15-50 years (2001-2018) was conducte...

Jan 14th, 2022 - Invasive candidiasis has high mortality rates in immunocompromised patients, causing serious health problems. In mouse models, innate immunity protects the host by rapidly mobilizing a variety of resistance and tolerance mechanisms to systemic Can...

Jan 13th, 2022 - Recurrent vulvovaginal candidiasis (RVVC), also known as recurrent yeast infections, is defined as at least 3 episodes of acute VVC in the past 12 months. Several properties of oteseconazole (VT-1161) suggest that it might be a safer and more effe...

Jan 12th, 2022 - Candida albicans is the fungus responsible for oral candidiasis, a prevalent disease. The development of antifungal-based delivery systems has always been a major challenge for researchers. This study was designed to develop a nanostructured lipid...

Nov 2nd, 2019 - British HIV Association/British Infection Association guidelines on the management of opportunistic infection in people living with HIV: The clinical management of Candidiasis 2019.|2019|Dockrell DH,O’Shea D,Cartledge JD,Freedman AR,|diagnosis,dru...

Aug 31st, 2019 - Background: Fungal infections are of increasing incidence and importance in immunocompromised and immunocompetent patients. Timely diagnosis relies on appropriate use of laboratory testing in susceptible patients.Methods: The relevant literature r...

Dec 25th, 2016 - The European Conference on Infections in Leukemia (ECIL) provides recommendations for diagnostic strategies and prophylactic, pre-emptive or targeted therapy strategies for various types of infection in patients with hematologic malignancies or he...

Aug 2nd, 2014 - Xerostomia, also known as "dry mouth," is a common but frequently overlooked condition that is typically associated with salivary gland hypofunction, which is the objective measurement of reduced salivary flow. Patients with dry mouth exhibit symp...

Oct 25th, 2013 - Intra-abdominal candidiasis: the guidelines-forgotten non-candidemic invasive candidiasis.|2013|Montravers P,Dupont H,Eggimann P,|therapeutic use,drug effects,drug therapy,microbiology,drug therapy,microbiology,

Jan 19th, 2022 - Anticytokine autoantibodies are an important and emerging cause of disease. Anticytokine autoantibody-associated diseases include disseminated nontuberculous mycobacterial infection caused by anti-interferon- >= autoantibodies, severe mucocutaneou...

Jan 13th, 2022 - Recurrent vulvovaginal candidiasis (RVVC), also known as recurrent yeast infections, is defined as at least 3 episodes of acute VVC in the past 12 months. Several properties of oteseconazole (VT-1161) suggest that it might be a safer and more effe...

Jan 10th, 2022 - This is a Phase II randomized, double-blind, placebo-controlled study screening approximately 600 adult females, aged 18-55, with a goal to enroll approximately 250 participants to achieve 200 evaluable participants at the test of cure (TOC) visit...

Jan 5th, 2022 - This is a multicenter, randomized, double-blind study of two treatment regimens for invasive candidiasis included candidemia. Subjects will receive intravenous echinocandin followed by oral ibrexafungerp (SCY-078) vs intravenous echinocandin follo...

Dec 20th, 2021 - Recurrent vulvovaginal candidiasis (RVVC), also known as recurrent yeast infections, is defined as at least 3 episodes of acute VVC in the past 12 months. Several properties of oteseconazole (VT-1161) suggest that it might be a safer and more effe...

Nov 12th, 2021 - The US Food and Drug Administration (FDA) has granted orphan drug designation approval of miltefosine (Profounda, Inc) for the treatment of invasive candidiasis. This condition includes the potentially life-threatening candidemia, which is among t...

Sep 30th, 2021 - A phase 3 randomized, double-blind, controlled trial has shown that oteseconazole (Mycovia Pharmaceuticals), an oral antifungal agent, is safe and effective in treating acute and recurrent yeast infections (vulvovaginal candidiasis [VVC]) and in p...

Sep 2nd, 2021 - For patients who present with pesky vulvovaginal candidiasis, consider a course of ibrexafungerp, a first-in-class oral triterpenoid antifungal drug that was approved in June 2021, Aruna Venkatesan, MD, recommends. Dr.

Aug 25th, 2021 - Bimekizumab has been approved by the European Commission for the treatment of moderate to severe plaque psoriasis in adults, according to a statement from the manufacturer. Bimekizumab (Bimzelx), a humanized IgG1 monoclonal antibody, is the first ...

Jul 2nd, 2021 - The Food and Drug Administration has expanded the approval of secnidazole to include treatment of trichomoniasis in adults, according to a statement from manufacturer Lupin Pharmaceuticals. Trichomoniasis vaginalis is a common, nonviral, curable s...